From Discovery To Development To Delivery
AZBio is committed to building a top-tier life science industry in Arizona.
AZBio Members Are Making LIFE Bettter
AZBio Members discover, develop, and deliver life-saving and life-changing innovations.
Get Connected With Arizona's Bioindustry
A key component in Arizona’s life science ecosystem, the Arizona Bioindustry Association (AZBio) is the only statewide organization exclusively focused on Arizona’s bioscience industry. AZBio membership includes patient advocacy organizations, life science innovators, educators, healthcare partners and leading business organizations. AZBio is the statewide affiliate of the Biotechnology Innovation Organization (BIO) and works in partnership with AdvaMed, MDMA, and PhRMA to advance innovation and to ensure that the value delivered from life-changing and life-saving innovation benefits people in Arizona and around the world.
Success Stories – Good News from Arizona’s BioIndustry
Kacey Ernst testifies before a U.S. House subcommittee, saying that a recent study expects the Aedes aegypti mosquito to increase in numbers across the South and East.
The Ensuring Patient Access to Critical Breakthrough Products Act, will help bridge a gap between FDA and CMS and improve patient access to breakthrough medical technologies for serious illnesses, S. 2998, to expedite CMS decision-making for innovative medical technologies.
The biopharmaceutical industry is a major contributor to the U.S. economy, and also has a growing presence in Arizona, according to a new report released by TEConomy Partners LLC. Since 2000, members companies of PhRMA have invested more than half a trillion dollars in the search for new treatments and cures, including an estimated […]
Insys Therapeutics Successfully Completes Safety and Pharmacokinetic (PK) Study of Cannabidiol Oral Solution in Pediatric Epilepsy Patients
PHOENIX, May 24, 2016 (GLOBE NEWSWIRE) — Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “the Company”) today announced that it has successfully completed its Phase 1/Phase 2 safety and pharmacokinetic (PK) study in pediatric subjects with treatment-resistant epilepsy.